1. Biology and Prognosis of Diffuse Large B-Cell and Mantle Cell Lymphoma

2. Biology and Prognosis of Peripheral T-Cell Lymphomas

3. Lymphoma Biology and Mechanisms of Disease

4. Lymphoma Biology: Functional Imaging, Follicular, and Indolent B-Cell Lymphomas

5. Lymphoma: Chemotherapy, excluding Pre-Clinical Models I

6. Lymphoma: Chemotherapy, excluding Pre-Clinical Models II

7. Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents I

8. Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents II

9. Novel and Targeted Therapy of Non-Hodgkin Disease (NHL)

10. Treatment of Aggressive Lymphoma

11. Treatment of Low-Grade and Follicular Lymphoma

12. Clinical Results: Allogeneic Matched Related Donor Transplantation I

13. Clinical Results: Unrelated Donor Transplantation

14. Immunochemotherapy of Diffuse Large B-Cell Lymphoma

15. Lymphoma Biology with a Focus on the Germinal Center

16. Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents I

17. Recurrence after Allogeneic Transplantation

18. Clinical Care: Acute and Chronic Graft-Versus-Host Disease (GVHD) and Infectious Complications of Transplantation

19. Clinical Care: Acute and Chronic Graft-Versus-Host Disease (GVHD) Transplantation

20. Clinical Care: Acute and Chronic Graft-Versus-Host Disease (GVHD), Infectious Complications, and Immune Reconstitution of Transplantation

21. Clinical Care: Infectious Complications of Transplantation

22. Clinical Care: Novel Regimens and Engraftment

23. Clinical Results: Allogeneic Matched Related Donor Transplantation I

24. Clinical Results: Allogeneic Matched Related Donor Transplantation II

25. Clinical Results: Autologous Transplantation - Hodgkin and Non-Hodgkin Lymphoma

26. Mobilization Studies and Hematopoietic Cell Quality

27. Biology of T-Cell Lymphomas

28. Clinical Care: Novel Transplant Preparative Regimens

29. Clinical Results: Autologous Transplantation - Non-Hogkin Lymphoma

30. Health Services and Outcomes Research: Lymphoma

31. T-Cell Lymphoma: Primary Central Nervous System (CNS) Lymphoma

32. Immunochemotherapy of Indolent Lymphoma, including Radioimmunotherapy (RIT)

33. Phase II/III of Diffuse Large B-Cell Lymphoma (DLBCL): Follicular Lymphoma

34. Targeted Therapy of Non-Hodgkin Lymphoma (NHL)

35. Lymphoma Biology: Gene Expression and Prognosis in Diffuse Large B-Cell Lymphomas

36. Lymphoma Biology: Susceptibility, Familial Risk, and Follicular Lymphoma Biology

37. Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents II

Biology and Prognosis of Diffuse Large B-Cell and Mantle Cell Lymphoma

[2022] HGAL – A Germinal Center-Like Diffuse Large B-Cell Lymphoma Prognostic Biomarker Interacts with the Cytoskeleton and Influences Cell Migration.

[2023] Neither Germinal Center (GC) vs Non-Germinal Center (Non-GC) Phenotype nor FOXP1 Expression Correlate with Outcome in AIDS-Associated Diffuse Large B-Cell Lymphoma (DLBCL): Study of Patients from AIDS Malignancies Consortium Trials 010 and 034.

[2024] Unveiling the Role of MicroRNA155 in Diffuse Large B Cell Lymphoma.    

[2025] Chromosomal Aberration Patterns of Aggressive B-Cell Lymphomas Closely Correlate with Molecularly Defined Disease Subtypes and Regional mRNA Expression. An Analysis of 213 Tumor Samples within the German MMML Network.

[2026] Isolated Brain Parenchyma Relapse of Non-Hodgkin's Lymphoma (NHL): A Descriptive Analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG).

[2027] Correlation of DNA Copy Number, Gene Expression, Protein Expression and Clinical Outcome in a Group of Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with CHOP Plus Rituximab (CHOP-R).

[2028] Germline Single Nucleotide Polymorphisms (SNPs) in IL1A, IL6, IL10, and IFNGR2 in Combination with Clinical with Demographic Factors Predict Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL).

[2029] Gene Expression Profiling of Diffuse Large B-Cell Lymphomas Supervised by CD21 Expression.

[2030] Significance of c-myc Rearrangements in Diffuse Large B-Cell Lymphoma.

[2031] Bone Marow (BM) Involvement in Diffuse Large B Cell Lymphoma (DLBCL): Clinical Impact of Discordant Disease.

[2032] Treatment Effect of Rituximab Plus Chemotherapy Is Obtained by Improving Survival from Non-Germinal Center-Type Untreated Diffuse Large B-Cell Lymphoma.

[2033] YY1 Expression Predicts Survival in Follicular and Diffuse Large B-Cell Lymphoma.

[2034] Expression of FOXP1 in a Poor Prognostic Sub-Group of DLBCL Is Associated with Deregulated Expression of AID.

[2035] Clinical and Pathological Prognostic Markers for Survival in Adult Patients with Post-Transplant Lymphoproliferative Disorders (PTLD), BCL2 Is a Poor Prognostic Marker in PTLD.

[2036] Identification of CSF Biomarkers for the Diagnosis of CNS Lymphoma.

[2037] Tissue Microarray (TMA) Study in DLBC Lymphomas (DLBCL): Could the Extranodal Origin Affect the Prognostic Impact of the Analysis?

[2038] Activation of the Endoplasmic Reticulum (ER) Unfolded Protein Response (UPR) in Aggressive B-Cell Lymphomas.

[2039] Loss of Major Histocompatibility Class II (MHCII) Gene Expression in Diffuse Large B Cell Lymphoma (DLBCL) Is Not Generally Due to Genetic Mutations in the Coding Regions of CIITA or RFX.

[2040] Induced Major Histocompatibility Class II (MHCII) Expression Does Not Alter Chemosensitivity, Radiosensitivity, Redox Potential, or Proliferation Rate in a CIITA-Transfected Diffuse Large B Cell Lymphoma (DLBCL) Cell Line.

[2041] Prognostic Analysis of Aberrant Somatic Hypermutation of RhoH in Diffuse Large B Cell Lymphoma.

[2042] Testicular Diffuse Large B-Cell Lymphoma of Activated B-Cel Subtype Is Frequently Associated with Clonally Related Non-Follicular Small B-Cell Lymphoma in the Bone Marrow.

[2043] Association between Drug-Metabolizing Enzymes Polymorphisms and Diffuse Large B-Cell Lymphoma Risk in the Middle Eastern Population.

[2044] A Small Subset of CD5-Negative Diffuse Large B-Cell Lymphomas Express Nuclear Cyclin D1 with Evidence of Amplified Cyclin D1 Signals or the t(11;14) Translocation.

[2045] High Grade Non-Hodgkin's Lymphoma with Tandem t(14;18) and c-MYC Rearrangement Is a Pathological Lymphoma Entity with Aggressive Clinical Presentation and Very Poor Prognosis.

[2046] Sonic Hedgehog Signaling in Mantle Cell Lymphoma.

[2047] Hypermutation in Mantle Cell Lymphoma Does Not Indicate a Clinical or Biological Sub Entity.

[2048] Cell Adhesion Induces p27Kip1-Associated Cell-Cycle Arrest through Down-Regulating SCF^Skp2 Ubiquitin Ligase Pathway in Mantle Cell and Other Non-Hodgkin's B-Cell Lymphomas. Session Type: Poster

[2049] Clinicopathologic Subtypes of Mantle Cell Lymphoma (MCL) Show Distinct Patterns of Genetic Copy Number Alteration.

[2050] Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma (ALCL): Results of the European Intergroup Study.

Biology and Prognosis of Peripheral T-Cell Lymphomas

[2051] Aberrant Expression of IL-2R in Pediatric Anaplastic Large Cell Lymphoma: Cellular and Proteomic Analysis of Denileukin Diftitox (ONTAK) as a Potential Therapeutic Agent.

[2052] International T-Cell Lymphoma Classification Project: Angioimmunoblastic T-Cell Lymphoma.

[2053] The Expression of T Cell Receptor Signaling Genes Is Associated with Poor Response to IFN-α and/or PUVA in Mycosis Fungoides.

[2054] Array CGH Analysis for PTCL-U Revealed Two Genetically Distinct Subgroups.  

[2055] Prognostic Significance of Ki-67 Expression in Extranodal NK/T Cell Lymphoma, Nasal Type: A Proposed Prognostic Index, KLABS Index.

[2056] Outcome-Related Genome Loci in T-Cell Non-Hodgkin's Lymphoma Identified by High-Resolution SNP-Typing Arrays.

[2057] NPM-ALK Promotes Cell Cycle Progression through Activation of JNK and c-Jun in Anaplastic Large Cell Lymphoma.

[2058] The Oncogenic Fusionprotein NPM-ALK Cooperates with Bcl2 To Induce T-Cell Lymphomas in Mice.

[2059] Adult T-Cell Leukemia/Lymphoma: A Clinicopathologic Study of 126 Cases from the International T-Cell Lymphoma Project.

[2060] Predictive Value of Clonal Peripheral Blood γTCR Rearrangement in Patients with Peripheral T-Cell Lymphoma.

Lymphoma Biology and Mechanisms of Disease

[2368] BAFF-R Receptor Also Functions in the Nucleus of Normal and Neoplastic Human B Lymphocytes.

[2369] C-Terminal Deletion Mutation of CD20 in B-Cell Malignancy Is Related to a Risk of Relapse and Resistance to Chimeric Anti-CD20 Antibody Therapy.

[2370] EBV Can Induce Somatic Hypermutation in Naïve B Cells In Vitro but Ig Class Switching Requires T Cell Help.

[2371] The Role of the Transcription Factor NFAT in the Pathogenesis of Non-Hodgkin's Lymphomas.

[2372] Novel siRNA Expressing Lymphoma Model Identify Distinct Molecular Mechanisms Regulating NFkB1 and NFkB2 Induced Cell Proliferation.

[2373] Rituximab-Mediated Inhibition of the p38 MAPK and NF-κB Survival Pathways In Vitro and Validation in Nude Mice Bearing the Raji B-NHL Tumor.

[2374] Rituximab-Mediated Upregulation of PTEN Expression and Inhibition of Both the PI3K/AKT Pathway and Pleitrophin (PTN) Expression in B-NHL: Roles in Cell Growth Inhibition and Chemosensitization.

[2375] Gene Expression Profiling Comparison between the Major Mature B-Cell Neoplasms and Their Normal Cellular and Anatomic Counterparts: Identification of Candidate Genes Potentially Involved in Lymphomagenesis.

[2376] TRAF6 and C-myb Show Novel Functions in the Nucleus of Lymphoma B Cells.

[2377] Bioluminescence Imaging of Spontaneous Lymphomas and Contribution of Distinct NFΚB Pathways.

[2378] Bone Marrow Stroma (BMS) Prevents Apoptosis of Lymphoma Cells by Upregulation of BMS-Derived B-Cell Activating Factor (BAFF) and Activation of NF-kB.

[2379] 53BP1 Is Targeted to Sites of DNA Breaks within the Immunoglobulin Heavy Chain Locus and Promotes Class Switch Recombination.

[2380] Regulation of pri-miRNA BIC Transcription and Processing in Burkitt Lymphoma.

[2381] B Cell Lymphomas Are Resistant towards Bone Morphogenetic Protein (BMP) Induced Growth Inhibition.

[2382] Impact of IL-10 Polymorphisms in Survival of Lymphoid Neoplasms.

[2383] Alternative Splicing Generates a BCL6 Isoform Encoding a Compact Repressor.

[2384] Role of Huntingtin Interacting Protein HIP-1 in Non-Hodgkin's Lymphoma.

[2385] Novel Diagnostic Scheme for Follicular Dendritic Cell Neoplasm: Clinicopathologic Analysis of 146 Cases.

[2386] Aberrant Methylation of SHP-1 (SH2-Containing Phosphatases 1) and SOCS-1 (Suppressor of Cytokine Signalling 1) Genes in Immunodeficiency-Related Lymphomas.

[2387] Rituximab-Mediated Sensitization of B-NHL Cells Lines to TRAIL-Induced Apoptosis: Involvement of YY1 Suppression and DR5 Upregulation.

[2388] The IMiDs® Immunomodulatory Drugs Revlimid® (Lenalidomide) and CC-4047 Induce Growth Arrest and Apoptosis in NHL Tumor Cells In Vitro.

[2389] Adult Weight Gain and Risk of Developing Non-Hodgkin Lymphoma (NHL): Results from a Large Prospective Cohort Study of Older Women.

[2390] Targeting xIAP Is More Important Than Bcl-Xl in Lymphomas with Constitutive Activation of NF-kB.

[2391] Induction of RKIP and Inhibition of the Transcription Repressor YY1 in B-NHL by the Novel Proteasome Inhibitor NPI-0052 and Sensitization to TRAIL-Induced Apoptosis.

[2392] Peroxisome Proliferator-Activated Receptor Gamma Promotes the Survival of Human T Lymphoma Cells through Its Regulation of Cellular Metabolism.

[2393] Motexafin Gadolinium (Mgd), a Redox Stress Inducer, Lowers p53 Protein but Not Message in Lymphoma Cell Lines: Mechanisms of Reactive Oxygen Species (ROS)-Mediated Apoptosis in Lymphoma.

[2394] Polymorphisms of Thymidylate Synthase in the 5'- and 3'-Untranslated Regions Associated with Risk of Non-Hodgkin's Lymphoma.

[2395] The PIG-A Gene Is Hypermutable in Lymphoid Neoplasms.

[2396] Host Immunogenetic Single Nucleotide Polymorphisms (SNPs) Predict Overall Survival in Small Lymphocytic Lymphoma.

[2397] Identification of Circulating Autoantibodies in Patients with Lymphoma Using Antigen Arrays.

Lymphoma Biology: Functional Imaging, Follicular, and Indolent B-Cell Lymphomas

[2398] FDG PET-CT in Primary Staging and Management of Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL): Experience in 465 Consecutive Patients.

[2399] FDG-PET Scans as a Staging Study for T-Cell Lymphomas: High Rates of Positivity Do Not Result in Frequent Changes in Stage.

[2400] Blinded Mid-Treatment FDG-PET in Newly Diagnosed Aggressive Non-Hodgkin Lymphoma (NHL): First Results of a Prospective Multicenter Study.

[2401] High Incidence of False Positive PET Scans in Patients with Aggressive Non-Hodgkins Lymphoma Treated with Rituximab-Containing Regimens.

[2402] Majority of Transformed Lymphomas Have High SUVs on PET Scanning Similar To Diffuse Large B Cell Lymphoma (DLBCL).

[2403] Clinical Usefulness and Therapeutic Plan with Interim PET/CT Analysis in Malignant Lymphoma.

[2404] Achievement of FDG-PET Negativity Does Not Predict Durable Responses in T-Cell Lymphoma.

[2405] Value of FDG-PET in Prediction of Splenectomy Findings in Patients with Suspected or Known Lymphoma.

[2406] The Tumor Microenvironment Measured by Flow Cytometry Predicts Overall Survival (OS) and Transformation Risk (TR) in Follicular Lymphoma.

[2407] Deregulation of the Insulin-Like Growth Factor Type 1 Receptor (IGF-1R) in Transformed Follicular Lymphomas: Implications for Novel Therapy.

[2408] Evidence for Non-Random Immunoglobulin V_H Gene and Light Chain Isotype Usage in Follicular Non-Hodgkin's Lymphoma.

[2409] Human Mesenchymal Stem Cells Isolated from Bone Marrow and Lymphoid Organs Support Tumor B-Cell Growth: Implications in Follicular Lymphoma Pathogenesis.

[2410] Genomic Profiling of Follicular Lymphoma Identifies Novel High-Frequency Copy-Neutral Loss of Heterozygosity on Chromosomes 1p and 6p and Identifies Candidate Genes Involved in FL Biology.

[2411] Possible Role for Mutations in the Transactivation Domain of C-MYC in the Clinical Transformation of Follicular Lymphomas.

[2412] Cessation of Somatic Hypermutation of Immunoglobulin Genes in Follicular Lymphomas after Isotype Switching Despite Continuous Expression of Activation-Induced Cytidine Deaminase (AID).

[2413] Aberrant Somatic Hypermutation of Follicular Lymphoma Transformed To Diffuse Large B-Cell Lymphoma.

[2414] Quantitative Assessment of Circulating t(14;18) Positive Cells by RQ-PCR at Diagnosis and Follow-Up Correspond to Clinical Characteristics and Predicts Time to Treatment Failure in Follicular Lymphoma.

[2415] Transmission of a Follicular Lymphoma by Allogeneic Bone Marrow Tranplantation — Evidence to Support the Existence of a Lymphoma Progenitor Cell.

[2416] Molecular Mechanisms Regulating Resistance to the Akt Inhibitor Perifosine in Waldenstrom's Macroglobulinemia, the Role of the ERK and PKC Pathways.

[2417] The PI3K/Akt Pathway Is an Important Regulator of Homing and Adhesion in Waldenstrom's Macroglobulinemia.

[2418] The CXCR4/SDF-1 Axis Regulates Migration and Adhesion in Waldenstrom Macroglobulinemia.

[2419] Serum Free Light Chain (SFLC) Elevation Is Associated with High β2-Microglobulin and with a Shorter Time to Treatment in Waldenström Macroglobulinemia (WM).

[2420] Serum Free Light Chain in Waldenstrom Macroglobulinemia.

[2421] VH Gene Analysis in Splenic Marginal Zone Lymphoma Identifies Patients with Structurally Similar B Cell Receptors but Does Not Provide Prognostic Information.

[2422] Splenic Marginal Zone Lymphoma Shows a Distinct Pattern of DNA Copy Number Aberrations That Correlates with Tumor Characteristics and Predicts Disease Outcome.

[2423] Oligonucleotide Microarray Analysis of Ocular Adnexal MALT Lymphoma with Trisomy 18.

[2424] Genomic Imbalances Are Associated with Outcome of Helicobacter pylori Eradication in t(11;18)(q21;q21)-Negative Gastric MALT Lymphomas.

[2425] Infectious Disease Associations in Advanced Stage, Indolent Lymphoma (Follicular, FL and Non-Follicular, nFL): Developing a Lymphoma Prevention Strategy.

[2426] NOTCH2 Mutations in Marginal Zone Lymphoma.

[2427] Clinical Features and Prognostic Assessment of Nodal Marginal Zone B-Cell Lymphoma, a Rare Disease with Follicular-Like Behaviour.

Lymphoma: Chemotherapy, excluding Pre-Clinical Models I

[2428] Detection of Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin's Lymphoma (HL): Observations and Implications for Post-Remission Radiologic Surveillance.

[2429] Banoxantrone (AQ4N), a Tissue Targeted Prodrug: Results of a Phase 1 Study in Lymphomas.

[2430] Multicenter Phase I Studies To Evaluate the Safety, Tolerability, and Clinical Response to Intensive Dosing with the Proteasome Inhibitor PR-171 in Patients with Relapsed or Refractory Hematological Malignancies.

[2431] A Phase II Trial of CHOP Chemotherapy Followed by Yttrium 90 (⁹⁰Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.

[2432] Ifosphamide, Etoposide and Epirubicin (IVE) Is an Effective Combined Salvage and Peripheral Blood Stem Cell Mobilisation Regimen for Transplant-Eligible Patients with Lymphoma.

[2433] Very Early Post-Treatment PET/CT Scan Performed One Week after First Chemotherapy Course Compared Against the Standard PET after Third Course in Histologically Aggressive Lymphoma (NHL). Session Type: Poster Session, Board #611-II - 09:00 AM   

[2434] Early Response to a Short Course of Induction Chemotherapy Overcomes the Prognostic Role of IPI in Patients with Aggressive NHL. Preliminary Results of the GISL LA05 Trial. Session Type: Poster Session, Board #612-II - 09:00 AM   

[2435] A Short Weekly Chemotherapy Regimen (ACOP-B) Followed by Involved Field Radiotherapy in Limited Stage Aggressive Non-Hodgkin Lymphoma. Multicentric Analyses of Toxicity, Efficacy and Long Term Follow up.

[2436] Safety of Prophylactic Use of Darbepoetin Alfa in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP 14 or R-CHOP21: Preliminary Results of the LNH03-6B Randomized GELA Study.

[2437] CNOP (Mitoxantrone) Chemotherapy Is Inferior to CHOP (Doxorubicin) in the Treatment of Patients with Aggressive Non-Hodgkin Lymphoma (Review).

[2438] Intensifying Methotrexate (MTX) Dosage Reduces Treatment Failure in Adults with Burkitt or Burkitt-Like Leukaemia/Lymphoma (BL) Treated with an Adapted BFM Protocol.

[2439] Toxicity and Risk Factors Contributing to Delayed Methotrexate (MTX) Elimination in Adult/Elderly Patients (pts) Treated with High-Dose Methotrexate Therapy (HDMTX), a 2-Year, Single Center Survey.

[2440] Comprehensive Geriatric Assessment-Adapted Chemotherapy in 100 Elderly Patients (>70 Years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL).

[2441] Prolonged Hematologic Toxicity from the Hyper-CVAD Regimen; Manifestations, Frequency, and Natural History in a Cohort of 125 Consecutive Patients.

[2442] Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy.

[2443] Acquired Immunodeficiency and Malnutrition in Patients Treated with Bi-Weekly CHOP-Based Chemotherapy for Diffuse Large B-Cell Lymphoma.

[2444] Impact of Febrile Neutropenia and Colony Stimulating Factor Use on Chemotherapy Delivery in Patients with Lymphoma: Results from the INC-EU Prospective Observational European Neutropenia Study.

[2445] Clinicopathological Features of Pyothorax-Associated Lymphoma; a Retrospective Survey Involving 98 Patients.

[2446] Improvement of Overall Survival in Mantle Cell Lymphoma during the Last Decades.

[2447] GMCLI, Goelams Mantle Cell Lymphoma Index, a New Prognostic Index of Survival for MCL Patients Treated with VAD-C and Autologous PBSCT.

[2448] Durable Event-Free and Overall Survival (EFS/OS) in Mantle Cell Lymphoma (MCL) without Rituximab: Long-Term Follow-Up of a Phase II Trial with Intensive Chemotherapy (CTAP/VMAC) Followed by Autologous Hematopoietic Stem Cell Transplant (aHSCT). Session Type: Poster Session, Board #626-II - 09:00 AM   

[2449] High Dose Cytarabine Salvage Regimen Combined with Bortezomib Is Feasible and Highly Effective in Relapsed Mantle Cell Lymphoma.

[2450] Phase II Study of Enzastaurin in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.

[2451] Efficacy and Safety of DepoCyte® (Liposomal Cytarabine) in Patients with CNS Involvement from Non-Hodgkin's Lymphoma (NHL): A Report on 32 Patients Treated in Spain.

[2452] Necessity of Intraventricular Chemotherapy with the Modified Bonn Protocol in Primary CNS Lymphoma (PCNSL) Patients.

[2453] Phase II Trial of the Bonn Polychemotherapy Protocol with Deferred Radiotherapy in Patients with Primary Central Nervous System Lymphoma.

[2454] Prospective Management of Primary Testicular Lymphoma (PTL) with Doxorubicin-Based Chemotherapy, Prophylactic Intrathecal (IT) Methotrexate and Radiotherapy (RT), but without Rituximab: Results from IELSG.

[2455] Breast Non Hodgkin's Lymphoma (NHL): A Large Monocentric Study of Initial Characteristics, Natural History, and Prognostic Factors.

[2456] Primary Extranodal Follicular Lymphoma: Clinicobiological Features and Outcome.

[2457] FcγRIIIa Gene Polymorphisms May Correlate with Response to Frontline R-CHOP Therapy for Diffuse Large B-Cell Lymphoma.

Lymphoma: Chemotherapy, excluding Pre-Clinical Models II

[2459] Enteropathy-Type T-Cell Lymphoma: Clinical Features of a Series of 62 Cases. Jan Delabie, Harald Holte, Andrew Lister and Julie Vose for the International T-Cell Lymphoma Project.

[2460] Hepatosplenic T-Cell Lymphoma: Clinical Characteristics and Treatment Outcome.

[2461] A Phase II Study of Denileukin Diftitox (Ontak®) with CHOP Chemotherapy in Patients with Newly-Diagnosed Aggressive T-Cell Lymphomas, the CONCEPT Trial: Interim Analysis.

[2462] Phase II Study of Proteasome Inhibitor Bortezomib (Velcade®) in Patients with Relapsed/Refractory T-Cell Lymphoma: Preliminary Results.

[2463] Front-Line Consolidation with Autologous Stem Cell Transplantation in Patients with Nodal Aggressive Peripheral T-Cell Lymphoma (PTCL). A Prospective Study of the GEL-TAMO.

[2464] The VIP-ABVD Regimen Is Not Superior to the CHOP 21 for the Treatment of Non Epidermotropic Peripheral T Cell Lymphoma. Final Results of the "LTP95" Protocol of the GOELAMS. Session Type: Poster Session, Board #642-II - 09:00 AM   

[2465] Peripheral T-Cell Lymphoma-Unspecified (PTCL-U) and NK/T-Cell Lymphoma Showed a Significantly Poor Prognosis in a Randomized Controlled Trial (RCT) JCOG9002 with Multidrug Combination Chemotherapy for Aggressive Lymphoma. Session Type: Poster Session, Board #643-II - 09:00 AM   

[2466] Cutaneous T Cell Lymphoma: Responses in Phase 1 Trial of Combination Therapy with Liposomal Doxorubicin, Bortezomib, and Gemcitabine. Session Type: Poster Session, Board #644-II - 09:00 AM   

[2467] Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study. Session Type: Poster Session, Board #645-II - 09:00 AM   

[2468] Romidepsin (Depsipeptide, FK228) Induces Clinically Significant Responses in Treatment-Refractory CTCL: Interim Report of a Phase II Multicenter Study. Session Type: Poster Session, Board #646-II - 09:00 AM   

[2469] Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers. Session Type: Poster Session, Board #647-II - 09:00 AM   

[2470] Surgical Resection Alone in Children with Limited Stage Lymphocyte Predominant Hodgkin's Lymphoma – The Experience of the EuroNet-PHL Group. Session Type: Poster Session, Board #648-II - 09:00 AM   

[2471] Treatment of Children & Adolescents with Early Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma with a Low Intensity Short Duration Chemotherapy Regimen [CVP] – on Behalf of the EuroNet-PHL Group. Session Type: Poster Session, Board #649-II - 09:00 AM   

[2472] Hodgkin Lymphoma in Very Young Children Can Be Treated Successfully without Radiation Therapy. Session Type: Poster Session, Board #650-II - 09:00 AM   

[2473] Identification of Prognostic Factors in Early Unfavorable Stage Hodgkin's Lymphoma (HL): An Individual Patient Data Meta-Analysis. Session Type: Poster Session, Board #651-II - 09:00 AM   

[2474] Risk-Oriented Therapy in Adults Previously Untreated Hodgkin's Lymphoma (HL) with ABVD Followed by Involved Field Radiotherapy (IFRT). Final Results of the Argentinian Group for Treatment of Acute Leukemia (GATLA) Phase III Study. Session Type: Poster Session, Board #652-II - 09:00 AM   

[2475] Response-Based Chemotherapy and Involved Field Radiation for Intermediate Stage Hodgkin Disease. A GISL/NHLSG Trial. Session Type: Poster Session, Board #653-II - 09:00 AM   

[2476] 100% of Complete Response (CR) and Survival (FFP, OS) in Newly Diagnosed Patients with Advanced- and Intermediate-Stage Hodgkin's Lymphoma (HL) Treated with Six Cycles of Dose-Dense, Dose-Intense (DD-DI) ABVD without Radiotherapy (RT).

[2477] Bortezomib Is Not Active in Patients with Relapsed Hodgkin's Lymphoma: Results of a Prematurely Closed Phase II Study.

[2478] A Phase II Trial of FM (Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (⁹⁰Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Indolent Non-Follicular Lymphoma Patients.

[2479] A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (⁹⁰Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Follicular Lymphoma (FL) Patients.

[2480] High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multicentre Phase II Study of the German Low Grade Lymphoma Study Group (GLSG).

[2481] Randomized Comparison of Cladribine Single (C) or in Combination with Cyclophosphamide (CC), and COP in Previously Untreated Low Grade B-Cell Non-Hodgkin Lymphoma Patients.

[2482] Early Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma.

[2483] Molecular Inhibition of mTOR with Temsirolimus (TORISEL™, CCI-779) Is a Promising Strategy in Relapsed NHL: The University of Chicago Phase II Consortium.

[2484] Imatinib Mesylate (Gleevec®) Is Active in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-140.

[2485] Cladribine in Weekly Versus Daily Schedule for Untreated Active Hairy Cell Leukemia: Final Report of Polish Adult Leukemia Group (PALG) Prospective, Randomized, Multicenter Trial.

[2486] Lympho Node Enlargement in Adult's Patients Referred to Hematologist: A Frequent Not Classified Clinical Problem. Results from a Retrospective Study.

Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents I

[2487] Bcl-2 Antagonist ApoGossypol (NSC736630) Displays Single-Agent Activity in Bcl-2 Transgenic Mice and Has Superior Efficacy and Pharmacology with Less Toxicity Compared to Gossypol (N

[2488] Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom Macroglobulinemia.

[2489] Preclinical Efficacy of Campthothecin-Polymer Conjugate (IT-101) in Human Burkitt Lymphoma Bearing Mice.

[2490] Preclinical In Vitro and In Vivo Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenström's Macroglobulinemia (WM).

[2491] Coimmunization with Antigens Shared between Neoplastic and Normal B Cells Suppresses Induction of Strictly Tumor-Specific Cytotoxic T Cells through In Situ Activation of Regulatory T Cells.

[2492] SGN-70, a Humanized Anti-CD70 Antibody, Targets CD70-Expressing Hematologic Tumors.

[2493] Molecular Mechanisms of the mTOR Inhibitor Temsirolimus (CCI-779) Antiproliferative Effects in Mantle Cell Lymphoma: Induction of Cell Cycle Arrest, Autophagy, and Synergy with Vorinostat (SAHA).

[2494] Dynamic Assessment of Apoptosis for In Vitro Design of Bortezomib Combination Therapies for Lymphoid Malignancies.

[2495] Multivalent Anti-CD20/Anti-CD22 Bispecific Antibody Fusion Proteins Made by the DNL Method Show Potent Lymphoma Cytotoxicity.

[2496] The Selective Protein Kinase CΒ Inhibitor, Enzastaurin, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom's Macroglobulinemia.

[2497] Valproic Acid (VPA), a Histone Deacetylase (HDAC) Inhibitor, Diminishes Lymphoproliferation in the Fas Deficient MRL/lpr-/- Murine Model of Autoimmune Lymphoproliferative Syndrome (ALPS).

[2498] Inhibiton of mTOR by RAD001 Restores Normal B Cell Differentiation and Prevents B Cell Lymphomas in Eμ-MYC Mice.

[2499] The Humanized Anti-CD40 Antibody, SGN-40, Promotes Apoptosis Signaling and Is Effective in Combination with Standard Therapies in Lymphoma Xenograft Models.

[2500] Extracorporeal Adsorption Following Infusion of Radiolabeled Anti-CD20 Antibody Clears Unbound Radioimmunoconjugate from the Circulation and Reduces Radiation Exposure of Normal Organs in the Nonhuman Primate.

[2501] Macrophage Depletion Can Enhance Combined Radiation and Anti-CD40 Monoclonal Antibody Therapy of B-Cell Lymphoma.

[2502] Targeting BH3-Domain Anti-Apoptotic Proteins with GX15-070 Significantly Increases Rituximab-Mediated Antibody Dependent Cellular Cytotoxicity (ADCC) and Complement Mediated Cytotoxicity (CMC) Against B-Cell Lymphomas.

[2503] Interleukin-21-Induced Apoptosis and Cell Death of Diffuse Large B-Cell Lymphoma (DLBCL) Cell Lines and Primary Tumors Are Associated with an Induction of Bim.

[2504] Mechanistic Evaluation of Siplizumab (MEDI-507) Activity on Normal and Malignant T-Lymphocytes.

[2505] The C3b Component of Complement Inhibits NK Cell Activation Induced by Rituximab-Coated Target Cells.

[2506] Nutlin-3A, an MDM2 Antagonist, Induces p53-Dependent Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma (HL).

[2507] Human Macrophages Phagocytose Rituximab Opsonised Leukemic Cells Via CD16, CD32 and CD64 but Do Not Mediate ADCC.

[2508] Treatment with the Anti-CD20 Antibody (B1) and Irradiation Result in Synergistic Cytotoxicity That Is Dependent on MAPK Activation.

[2509] Synergistic Interaction of the Histone Deacetylase Inhibitor SAHA with the Proteasome Inhibitor Bortezomib in Mantle Cell Lymphoma.

[2510] Activity of Bendamustine (TREANDA™) in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells with Alterations in DNA Damage Response Pathway.

[2511] Bortezomib Is a Novel Inducer of Latent Epstein Barr Virus (EBV) in EBV+ Lymphoma Cell Lines.

[2512] Bortezomib Synergizes with a Novel Jak2 Inhibitor, WP-1130, To Inhibit Cell Growth and Induce Apoptosis in “Classic” and “Blastoid-Variant” Mantle Cell Lymphoma.

[2513] Prenylation Inhibitors as Potential Therapeutic Drugs in Hodgkin Lymphoma.

[2514] Atiprimod Inhibits Growth of Mantle Cell Lymphoma In Vitro and In Vivo and Induces Apoptosis Via Activation of the Mitochondrial Pathway.

[2515] Nutlin-3a, an MDM2 Antagonist, Induces Cellular Senescence in Adult T-Cell Leukemia/Lymphoma Cells.

[2516] Thrombocytopenia Induced by CMC-544 and Its Amelioration Using Oprelvekin (Neumega®/Recombinant Human Interleukin-11).

Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents II

[2517] Novel Agent Perifosine Enhances Antitumor Activity of Bortezomib, Rituximab and Other Conventional Therapies in Waldenstrom's Macroglobulinemia.

[2518] Mistargeting of Normal Cells in Anti-CD30 Immunotherapy of Lymphoma Cells Is Blocked by Selective Metalloproteinase Inhibitor.

[2519] HCD122, an Antagonist Human Anti-CD40 Monoclonal Antibody, Inhibits Tumor Growth in Xenograft Models of Human Diffuse Large B-Cell Lymphoma, a Subset of Non-Hodgkins Lymphoma.

[2520] In Vitro Activity of SYK and BCR-ABL Inhibitors in Aggressive Lymphomas.

[2521] Recombinant Bispecific Monoclonal Antibody (bsMAb) Against CD20 and CD22 Active In Vitro and In Vivo Against B-Cell Lymphomas.

[2522] Lenalidomide (Revlimid®) Enhances Monoclonal Antibody-Associated Anti-Tumor Activity Against Rituximab-Sensitive and Rituximab-Resistant B-Cell Lymphoma Cell Lines.

[2523] Targeting BH3-Domain Anti-Apoptotic Proteins with GX15-070 Decreases DNA Synthesis, Induces Cell Death and Sensitizes Rituximab-Sensitive and Resistant Non-Hodgkin's Lymphoma Cell Lines to the Anti-Tumor Activity of Chemotherapy Agents.

[2524] Antibody-Drug Conjugates Targeted to CD79 for the Treatment of Non-Hodgkin's Lymphoma.

[2525] Anti-Adult T-Cell Leukemia Effects of a Novel Synthetic Retinoid, Am80 (Tamibarotene) through Inhibition of NF-κB.

[2526] Histone Deacetylase Inhibitor Promotes Rituximab-Induced Apoptosis in Non-Hodgkin's B-Lymphoma Cells by NF-kB-Mediated Bcl-2/Bcl-XL Downregulation and c-Myc Degradation.

[2527] Nano-Fluidic Detection of Oncoprotein Signaling in Preclinical and Patient Lymphoma Samples.

[2528] Preferential Inhibition of Malignant Cell Growth by CDDO in Waldenström Macroglobulinemia.

[2529] An Fc-Optimized Monoclonal Antibody Against CD32B, the Human Inhibitory Fc-_γ Receptor IIB, in the Immunotherapy of B-Cell Malignanacy.

[2530] Triterpenoids Display Single Agent Activity in a Mouse Model of CLL/SBL.

[2531] IRF-4 and Interferon Resistance in Adult T-Cell Leukemia/Lymphoma.

[2532] Inhibition of the Pan-Bcl-2 Family by the Small Molecule GX15-070 Induces Apoptosis in Mantle Cell Lymphoma (MCL) Cells and Enhances the Activity of Two Proteasome Inhibitors (NPI-0052 and Bortezomib), and Doxorubicin Chemotherapy.

[2533] Monocyte Colony-Stimulating Factor Enhances Rituximab-Dependent Cellular Cytotoxicity by Monocytes.

Novel and Targeted Therapy of Non-Hodgkin Disease (NHL)

[2709] Induction of Survivin-Specific, HLA-A24 Restricted Cytotoxic T Lymphocytes Using an Immunodominant Peptide; In-Vitro Feasibility Study and a Clinical Trial of Survivin Peptide Vaccination.

[2710] Phase II Results of Bendamustine in Combination with Rituximab in Relapsed Indolent and Mantle-Cell Non-Hodgkin's Lymphoma.

[2711] Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study.

[2712] Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

[2713] Combination Immunotherapy with a CpG Oligonucleotide and Rituximab (R) Augments the Immunological Response and Favorably Alters the Malignant Microenvironment of Follicular Lymphoma (FL).

[2714] Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

[2715] LBH589, a Novel Deacetylase Inhibitor (DACi), Treatment of Patients with Cutaneous T-Cell Lymphoma (CTCL). Skin Gene Expression Profiles in the First 24 Hours Related to Clinical Response Following Therapy.

[2716] Preliminary Report on a Phase I/II Study of Intratumoral Injection of PF-3512676 (CpG 7909), a TLR9 Agonist, Combined with Radiation in Recurrent Low-Grade Lymphomas. Session Type: Poster Session, Board #894-II - 09:00 AM   

[2717] Adaptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells Enhances Lymphocyte Recovery after Cyclophosphamide – Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma.

[2718] SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

[2719] Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 (hA20): Phase I/II Results.

[2720] High Dose ⁹⁰Yttrium Ibritumomab Tiuxetan (Zevalin) with PBSC Support in Refractory-Resistant NHL Patients: A Phase I/II Study.

[2721] A Phase II Immunochemotherapy Study with Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) in Peripheral T-Cell Lymphomas.

[2722] Phase 1 Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Lymphoma.   

[2723] Zanolimumab, a Fully Human Monoclonal Antibody: Preliminary Results of an Ongoing Clinical Trial in CD4⁺ Peripheral T-Cell Lymphomas (PTCL).

[2724] Penetration of Yttrium-90-Labeled Ibritumomab Tiuxetan (Zevalin™) into Primary CNS Lymphoma.

[2725] T Cell Responses during Long-Term Continuous Infusion of MT103 (MEDI-538; Anti-CD19 BiTE) in Patients with Relapsed B-NHL: Data from Dose-Escalation Study MT103-104.

[2726] Kinetics of Immune Responses and Tumor Burden in Patients with Indolent B Cell Lymphomas Receiving Recombinant Idiotype Vaccination as the Sole Treatment.

[2727] A Phase I Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia.

2728] CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) – Preliminary Results of Subjects with Castleman's Disease from a Phase 1 Study in Selected Hematological Malignancies.

[2729] Phase I/II Study of Ipilimumab (MDX-010), an Anti-CTLA-4 Monoclonal Antibody, in Patients with Follicular Non-Hodgkin Lymphoma.

[2730] Two Phase I Open-Label Studies of the Fully Human HLA-DR-Specific IgG₄ Monoclonal Antibody 1D09C3 in Patients with Relapsed and/or Refractory B-Cell Lymphoproliferative Neoplasias on a Weekly and Bi-Weekly Dosing Scheme.

[2731] Zanolimumab, a Fully Human Monoclonal Antibody: Early Results of an Ongoing Clinical Trial in Patients with CD4⁺ Mycosis Fungoides (MF) Type CTCL (Stage IB-IVB) Who Are Refractory or Intolerant to Targretin and One Other Standard Therapy.

[2732] Alemtuzumab (Campath-1H) in Patients with Erythrodermic Cutaneous T-Cell Lymphoma (E-CTCL): The Northwestern University Experience.

[2733] Phase II Preliminary Results of SGN-30 (Anti-CD30 mAb) in Patients with CD30+ Lymphoproliferative Disorders.

Treatment of Aggressive Lymphoma

[2734] First Report of the HOVON 45: A Phase II Study with Rituximab, High Dose Ara-C and Autologous Stem Cell Transplantation in the Primary Treatment of Mantle Cell Lymphoma. AM   

[2735] Response Assessment after an Inductive CHOP or CHOP-Like Regimen with or without Rituximab in 103 Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Integrating ¹⁸Fluorodeoxyglucose Positron Emission Tomography (PET) to the International Workshop Criteria (IWC).

[2736] Novel Treatment of Burkitt Lymphoma with Dose-Adjusted EPOCH-Rituximab: Preliminary Results Showing Excellent Outcome.

[2737] Immuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909.

[2738] Dose-Dense Rituximab in Combination with Biweekly CHOP-14 for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Phase-I/II and Pharmacokinetic Study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

[2739] Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level.

[2740] Abbreviated Treatment with EPOCH-Rituximab and HAART Suspension Is Highly Effective in AIDS-Related Lymphoma (ARL).

[2741] Phase II Study of High Dose Outpatient Cyclophosphamide and Rituximab, without Stem Cell Support, for Low Grade and Mantle Cell Lymphoma.

[2742] Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups.

[2743] Does Rituximab Influence the Prognostic Effect of Germinal Centre Phenotype in Diffuse Large B-Cell Lymphoma?

[2744] Favorable Influence of Rituximab with High Dose Sequential Chemotherapy (R-HDS) Programs and Autologous Stem Cell Transplantation (ASCT) in Salvage Treatment for Patients with Refractory or Relapsed B-Cell Non-Hodgkin's Lymphoma.

[2745] Rituximab-CHOP (R-CHOP) and Radiotherapy (RT) for Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).

[2746] Phase II Study of Rituximab and Cladribine (2-CDA) in Newly Diagnosed Mantle Cell Lymphoma (MCL) (N0189).

[2747] ⁹⁰Y-Zevalin® (⁹⁰Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) Consolidation of FCM Induction Chemotherapy in Mantle Cell Lymphoma (MCL) Patients: Results from the PLRG upon Completed Enrollment.

[2748] Serum Levels and Pharmacokinetic of Rituximab in Bi-Weekly R-CHOP in Elderly Patients with DLBCL Treated in the RICOVER-60 Trial.

[2749] Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

[2750] Combination Chemotherapy with CHOP-Daclizumab in HTLV-I Associated Adult T-Cell Leukaemia/Lymphoma.

[2751] Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone, Etoposide, Procarbazine and Cyclophosphamide) in Relapsed/Refractory Disease.

[2752] ⁹⁰Y Ibritumomab Tiuxetan and Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma.

[2753] Marked Activity of Bortezomib, Rituximab, and Dexamethason in Relapsed and Refractory Mantle Cell Lymphoma.

Treatment of Low-Grade and Follicular Lymphoma

[2754] Role of Different Frontline Regimens in Achieving Complete Response in Follicular Lymphoma: A Meta-Analysis of CR Rate and Its Relation to Hazard Rate for Disease Progression.

[2755] Mature Results of a Prospective Trial of Rituximab in Patients (Pt) with Post Transplant Lymphoproliferative Disorder (PTLD) Unresponsive or Ineligible for Reduced Immunosuppression (RIS).

[2756] Phase III Trial of Active Immunotherapy (FavId®, Id/KLH) Following Rituximab Induction Therapy: Clinical Responses in Patients (pts) with Follicular Non-Hodgkin's Lymphoma (fNHL).

[2757] Prognostic Significance of Quantitative t(14;18) PCR Monitoring in Advanced Stage Follicular Lymphoma Patients.

[2758] Results of a Phase I/II Trial of Pixantrone in Combination with Fludarabine, Dexamethasone, and Rituximab in the Treatment of Patients with Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (NHL).

[2759] The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

[2760] Combined Immunochemotherapy with Rituximab Improves Overall Survival in Patients with Follicular and Mantle Cell Lymphoma: Updated Meta-Analysis Results.

[2761] Cladribine (2-CDA) Plus Sequential Rituximab in Newly Diagnosed Disseminated Extranodal Marginal Zone B-Cell Lymphomas. A Phase II Study.

[2762] Induction with Fludarabine, Cyclophosphamide and Rituximab Followed by Maintenance with Rituximab: Results of a Prospective Study in 75 Patients (LNHF-03).

[2763] Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts). Final Results of FC + R Phase II Trial by the GISL.

[2764] Long Term Efficacy of Rituximab in B-Cell Post Transplantation Lymphoproliferative Disorders (B-PTLD): Update of the Multicenter, Open Label, Phase II Trial (M39037 TRIAL).

[2765] Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstrom's Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.

[2766] Incidence of Hepatitis B Reactivation in Association with Rituximab Therapy.

[2767] ⁹⁰Y Ibritumomab Tiuxetan (Y2B8, Zevalin®) Radioimmunotherap (RIT) Is Highly Effective for Relapsed or Refractory Indolent B-Cell Non-Hodgkin's Lymphoma (B-NHL) Pretreated with Rituximab-Containing Chemotherapy (R-Chemo): Japanese Multicenter Phase II Study. S

[2768] Excessive Neurotoxicity in a Phase II Trial of Combined Bortezomib and Rituximab in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin's Lymphoma.

[2769] Combined Immuno-Chemotherapy Followed by Rituximab Maintenance Is an Effective Salvage Treatment after Prior Rituximab Containing Therapy: Results of a GLSG-Subgroup Analysis in Patients with Relapsed Indolent Lymphoma.

[2770] Favorable Results of Rituximab in Combination with CHOP in the Front-Line Treatment of Follicular Lymphoma Grade 3.

[2771] Efficacy of ⁹⁰Y-Ibritumomab Tiuxetan (Zevalin) in Refractory or Relapsed MALT Gastric Non Hodgkin's Lymphoma.

Clinical Results: Allogeneic Matched Related Donor Transplantation I

[49] Outcomes after HLA-Matched Sibling Transplants or Chemotherapy in Children with Acute Lymphoblastic Leukemia in a Second Remission after an Isolated Central Nervous System Relapse. S

[50] Outcomes Following Syngeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Matched Comparison to Autologous Transplantation.

[51] Reduced Intensity Conditioning Regimen for Allografting Following Autografting Has Strong Anti-Myeloma Activity and Delays Disease Progression Compared to Tandem Autografting.

[52] Outcome of Patients with Aplastic Anemia Given First Line Transplantion or Immunosuppression in the Last Decade: A Report from European Group for Blood and Marrow Transplantation (EBMT).

[53] HLA-Matched Sibling Donor Stem Cell Mobilization Can Be Safely and Effectively Reduced from a Five Day to a One Day Process by a Direct Antagonist of the CXCR4/SDF-1 Interaction.

[54] A Distinct Pattern of Non-HLA Polymorphisms Predicts an Increased Risk for GvHD without Benefit of GvL in HLA Matched Sibling Transplants for Chronic Myeloid Leukemia (CML).

Clinical Results: Unrelated Donor Transplantation

[169] Volunteer Unrelated Donor PBSC Collection Efficacy and Recipient Outcomes: Results of a Prospective National Marrow Donor Program (NMDP) Trial, 1999-2003.

[170] Identification of Non-Permissive HLA Allele Mismatch Combinations and Amino Acid Substitution Responsible for Acute Graft-Versus-Host Disease in Unrelated Allogeneic Bone Marrow Transplantation.

[171] KIR Ligand Absence in Recipients of Unrelated Donor (URD) Allogeneic Hematopoietic Cell Transplantation (HCT) Is Associated with Less Relapse and Increased Graft Versus Host Disease (GVHD).

[172] Single or Multiple HLA-A, B, C or DRB1 Mismatches Limit Success of Unrelated Donor Bone Marrow Transplantation.

[173] Impacts of ABO-Blood Type Incompatibility on Outcome of Unrelated Bone Marrow Transplantation through the Japan Marrow Donor Program.

[174] Unrelated Donor Hematopoietic Cell Transplant (HCT) for Hemophagocytic Lymphohistiocytosis (HLH).

Immunochemotherapy of Diffuse Large B-Cell Lymphoma

[205] Six vs. Eight Cycles of Bi-Weekly CHOP-14 with or without Rituximab for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Completed RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

[206] DA-EPOCH-R Is Highly Effective in Both BCL-6+ and BCL-6- Untreated De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Study Update and Analysis of Survival Outcomes for Multiple Biomarkers.

[207] Benefit of Rituximab Addition to High-Dose Programs with Autograft for B-Cell Lymphoma: A Multicenter GITIL Survey on 957 Patients.

[208] Primary Diffuse Large B-Cell Lymphoma of the Testis (PTL): A Prospective Study of Rituximab (R)-CHOP with CNS and Contralateral Testis Prophylaxis. Results of the IELSG 10 Study.

[209] Primary Mediastinal Large B-Cell Lymphoma (PMBL) Outcome May Be Significantly Improved by the Addition of Rituximab to Dose-Adjusted (DA)-EPOCH and Obviates the Need for Radiation: Results from a Prospective Study of 44 Patients.

[210] Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin's Lymphoma in Elderly Patients.

Lymphoma Biology with a Focus on the Germinal Center

[223] Activation Induced Cytidine Deaminase (AID) Is Required for Germinal-Center Derived Lymphomagenesis.

[224] A Critical BCL6-Related Feedback Loop Explains the Unusual Biological Features of Germinal Center B-Cells and Their Malignant Transformation into B-Cell Lymphomas.

[225] BCL6 Programs Lymphoma Cells for Survival and Differentiation through Distinct Biochemical Mechanisms, Both of Which Can Be Therapeutically Targeted.

[226] Tonic B-Cell Receptor Signaling Promotes the Survival of Diffuse Large B-Cell Lymphomas: Identification of SYK as a Rational Treatment Target.

[227] The TNF Receptor, CD40 Enters Nucleus through Nuclear Pore Complex and Interacts with c-Rel in Aggressive B Cell Lymphoma.

[228] IgA and IgG Hypogammaglobulinemia Are Associated with Mutations in the APRIL/BLYS Receptor TACI in Waldenstrom's Macroglobulinemia (WM).

Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents I

[229] Novel 3^rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction.

[230] Efficacy of an Antagonistic Anti-CD40 Monoclonal Antibody, HCD122 (CHIR-12.12), in Preclinical Models of Human Non-Hodgkin's Lymphoma and Hodgkin's Disease.

[231] Specific Tumor Targeting and Potent Bystander Killing with SGN-35, an Anti-CD30 Antibody Drug Conjugate.

[232] Superior T Cell and Humoral Immunity Generated Against B Cell Lymphomas Using a Sulfhydryl-Based Idiotype Carrier Protein Conjugation Method.

[233] Antitumor Activity of Human CD34+ Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (mTRAIL).

[234] The Green Tea Extract Epigallocatechin Induces In Vitro Cell Death in Primary Human Lymphoma Cells through an ROS Dependent Mechanism.

Recurrence after Allogeneic Transplantation

[259] Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation.

[260] Lymphodepletion Followed by Donor Lymphocyte Infusions (DLI) Causes Significantly More Acute Graft Versus Host Disease Than DLI Alone.

[261] Low Pre-DLI Lymphocytes Counts Are Predictive of Good Disease Responses in Patients with Mixed Chimerism Following Campath-Containing Reduced Intensity Transplants.

[262] Outcomes among Patients with Recurrent High-Risk Hematologic Malignancy after Nonmyeloablative Versus Myeloablative Allogeneic Hematopoietic Cell Transplantation.

[263] Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplant: May We Predict Graft vs Leukemia without Graft vs Host Disease?

[264] Increased Leukaemia Free Survival (LFS) in Patients with Cytogenetic High Risk AML after Related or Unrelated Hematopoietic Cell Transplantation (HCT) Compared to Chemotherapy in the OSHO 96 and 2002 Studies.

Clinical Care: Acute and Chronic Graft-Versus-Host Disease (GVHD) and Infectious Complications of Transplantation

[2846] High Incidence of Cytomegalovirus Reactivation and Diseases Following Reduced-Intensity Cord Blood Transplantation for Adult Patients.

[2847] Respiratory Syncytial Virus Infections (RVS) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Palivizumab (P) Era.

[2848] Risk Factors for Late Infections after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Related Donor.

[2849] Breakthrough Fungal Infections after Allogeneic Hematopoietic Stem Cell Transplantation in Patients on Prophylactic Voriconazole.

[2850] Long Term Infectious Complications Following Reduced Intensity Conditioning (RIC) Allogeneic HLA-Identical Sibling Transplantation (allo-SCT).

[2851] Valganciclovir in the Prevention of Cytomegalovirus Following Allogeneic Stem Cell Transplantation.

[2852] Prognostic Factors for Survival in Invasive Aspergillosis in Adult Oncohematological Patients.

[2853] Hexon Specific T-Cells for Adoptive T-Cell Transfer as a Treatment of Adenovirus Infection after Allogeneic Stem Cell Transplantation.

[2854] The Role of Proteinase Inhibitor 9 (PI-9) in Granzyme B/Perforin-Mediated Cytotoxicity Induced by Cytotoxic T Cells in Allogeneic Hematopoietic Stem Cell Transfusion.

[2855] A High Proportion of CD4+CD25+ Lymphocytes Associates with a Risk of aGvHD and Inversely Correlate with Proportions of CMV and EBV Specific CD8+ Cells in Blood.

[2856] Potential Therapeutic Intervention Suggested by Profound Deficiency of Neutrophil-Derived Bactericidal/Permeability-Increasing Protein (BPI) and Other Alterations in LPS-Directed Innate Immunity after Myeloablative Hematopoietic Stem Cell Transplantation (HSCT).

[2857] Lung Resection for Invasive Pulmonary Aspergillosis in Neutropenic Patients with Hematologic Malignancies: Long Term Results in Thirty Two Cases.

[2858] Vaccine Properties of a Novel Marker Gene-Free Recombinant Modified Vaccinia Ankara (MVA) Expressing Immunodominant CMV Antigens.

[2859] Low Incidence of CMV Reactivation and Infection after Allogeneic Bone Marrow Transplantation (BMT) Incorporating Post-Transplantation Cyclophosphamide (Cy).

[2860] Multivariate Analysis of Patient and Graft Specific Factors among 330 Recipients of Unrelated Cord Blood Transplant (UCBT) To Predict Risk of Death from Opportunistic Infections in the First 6 Months after UCBT.

[2861] Validation of Serum Aspergillus Galactomannan Index as a Surrogate Endpoint for Outcome of Invasive Aspergillosis: Clinical and Research Implications.

[2862] Immunized Against Hepatitis B Virus Allografted Recipients Are at High Risk for Gradual Surface Antibody (HbsAb) Disappearance Post Transplant, Regardless of Adoptive Immunity Transfer: A Study of 82 Allografted Long Term Survivors.

[2863] Pharmacokinetics of Oral Maribavir, a Novel Anti-Cytomegalovirus Agent, in Subjects with Renal Impairment.

[2864] Autologous Serum Containing Platelet Derived Growth Factors (PDGFs) as Topical Treatment for "Sicca Syndrome" Associated with Chronic GvHD.

[2865] Adult Recipients of Matched Related Donor Blood Cell Transplants Given Pretransplant Antithymocyte Globulin Have Less Graft-Versus-Host Disease and Transplant-Related Mortality: Follow-Up of a Matched Pair Analysis.

[2866] The Use of Sirolimus Combined with Tacrolimus and Low-Dose Methotrexate Is Effective in Preventing Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation.

Clinical Care: Acute and Chronic Graft-Versus-Host Disease (GVHD) Transplantation

[2867] Tacrolimus and Sirolimus as GVHD Prophylaxis for HLA-MRD Allogeneic HCT Conditioned with 3 Regimens: Toxicity and Efficacy in 70 Patients.

[2868] Donor C3435T Polymorphism in the Multidrug Resistance 1 (MDR1) Gene Is Associated with the Incidence of Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

[2869] Alemtuzumab but Not ATG Decreases Natural Killer (NK) Cell Activity towards Tumor Targets in the Early Phase after Allogeneic Stem Cell Transplantation.

[2870] Long Term Outcome of Patients with Steroid Refractory Acute Intestinal Graft Versus Host Disease after Treatment with Pentostatin.

[2871] Ex-Vivo Reduction of Allograft T Cell Dose Does Not Prevent Acute Graft-vs-Host Disease after Reduced-Intensity Hematopoietic Stem Cell Transplantation.

[2872] Chronic GVHD Leads to Shortening of Telomeres in Subsets of Lymphoid Cells but Not in Granulocytes in Long-Term Survivors after Allogeneic HSCT.

[2873] Donor -173 G/C Polymorphism of Macrophage Migration Inhibitory Factor Gene Is Associated with the Development of Chronic Graft Versus Host Disease.

[2874] Deleterious Roles of the KIR Ligand Mismatch on Acute Graft Versus Host Disease in Unmanipulated HLA-Mismatched/Haploidentical Blood and Marrow Transplantation.

[2875] Rituximab Reduces the Incidence of Acute Graft Versus Host Disease in an Unselected Series of Twenty-One Patients Undergoing Allogeneic Stem Cell Transplantation at a Single Center.

[2876] Low Rates of Toxicity, GVHD, and Relapse Using Sirolimus (SRL)-Based GVHD Prophylaxis in Pediatric Related and Unrelated Transplant Recipients with High-Risk ALL.

[2877] Chemokine Profiling in Patients with Graft Versus Host Disease (GVHD) Following Allogeneic Blood Stem Cell Transplantation.

[2878] Single Nucleotide Polymorphism of CC Chemokine Ligand 5 Promoter Gene in Recipient May Affect on the Development of Chronic Graft-Versus-Host Disease and Its Severity after Allogeneic Transplantation.

[2879] Polymorphism in the Promoter Region of the Hemeoxygenase I Gene of the Donor Influences Overall Survival and Graft Versus Host Disease.

[2880] Plasma Proteomic Profiles May Predict Early Acute Graft-vs.-Host Disease (aGVHD) Following Reduced Intensity Conditioning (RIC) Allogeneic HLA-Identical Sibling Transplantation (allo-SCT).

[2881] Circulating B-Lymphocyte Subpopulations as Novel Biomarker for Measuring Activity of Chronic Graft-Versus-Host Disease.

[2882] Early Reconstitution of Natural Killer Cells Following Non-Myeloablative Hematopoietic Stem Cell Transplantation Predicts the Development of Acute Graft-Versus-Host Disease.

[2883] Tacrolimus Versus Cyclosporine for Graft-Versus-Host Disease Prophylaxis in Pediatric Patients Undergoing Matched Unrelated Donor Hematopoietic Stem Cell Transplants. A Pediatric Blood and Marrow Transplant Consortium Study.

[2884] Incidence and Outcome of Chronic Graft-Versus-Host Disease (cGVHD) Using National Institute of Health (NIH) Criteria.

[2885] Preferential Th2 Polarization at the Onset of Thrombotic Microangiopathy (TMA): Immunological Comparison of TMA Versus Acute GVHD in Terms of Peripheral T Cell Subsets, Dendritic Cell Subsets and Cytokine Profiles.

[2886] Graft Versus Host Disease Prophylaxis with Everolimus and Tacrolimus in Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukaemia (AML) Receiving Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).

[2887] Influence of Human Leukocyte Antigen Haplotypes on Acute Graft Versus Host Disease Incidence after Allogeneic Hematopoietic Stem Cell Transplantation.

[2888] Campath 1H Versus ATG for the Prophylaxis of Graft Versus Host Disease Does Not Increase the Risk of Relapse or Infections.

[2889] Infliximab for the Treatment of Chronic Graft Versus Host Disease. Session Type: Poster Session, Board #118-III - 10:30 AM   

[2890] Serum Proteomic Profiling and Study of Haptoglobin Polymorphisms in Patients with Chronic GVHD after Allogeneic Hematopoietic Stem Cell Transplantation.

[2891] Post-Transplantation High-Dose Cyclophosphamide (Cy) Is Effective Single Agent GVHD Prophylaxis That Permits Prompt Immune Reconstitution after Myeloablative HLA Matched Related and Unrelated Bone Marrow Transplantation (BMT).

[2892] Mycophenolate Mofetil (MMF) with or without Tracolimus (FK506) as a Second Line Treatment for Steroid-Resistant Acute Graft-Versus-Host Disease. The Experience of Saint Louis Hospital. Session Type: Poster Session, Board #121-III - 10:30 AM   

[2893] Dendritic Cell Type 2 Counts on Day 28 in HLA-Matched Related Allogeneic PBSCT Predicts the Incidence of Acute and Chronic GVHD.

[2894] Membranous Glomerulonephritis and Nephrotic Syndrome as a Late Manifestation of Chronic Graft-Versus-Host Reaction Following Allogeneic Transplantation for Hematologic Malignancy.

[2895] Predicting Steroid Refractroy Acute Gastrointestinal (GI) Acute Graft Versus Host Disease (AGVHD) by Assessment of Crypt Loss at Diagnosis.

[2896] Acute Graft Versus Host Disease (GVHD) Is Increased in Patients Receiving Cyclosporine/Cellcept as Frontline Prophylaxis Against GVHD in Pediatric Patients Undergoing Allogeneic Stem Cell Transplantation.

Clinical Care: Acute and Chronic Graft-Versus-Host Disease (GVHD), Infectious Complications, and Immune Reconstitution of Transplantation

[2897] Global Assessment of B Cell Alloimmunity Using 5000 Human Protein Microarrays.

[2898] Long-Term Follow-Up of Allogeneic Stem Cell Transplantation (SCT) with Reduced Intensity Conditioning (RIC) for Patients (pts) with Chronic Myeloid Leukemia (CML).

[2899] Impact of gamma/delta TCR⁺, Foxp3⁺ and Toll-Like Receptor Expressing T-Cells on the Outcome of Patients Receiving Unrelated Peripheral Blood Stem Cell Transplantation.

[2900] Transplantation of Positive Selected Peripheral Stem Cells with Add-Back of T Cells from Unrelated Donors in Children: Favourable Survival and Low Incidence of GvHD.

[2901] De-Escalation of the Alemtuzumab Dose Prior to Nonmyeloablative HLA-Identical Sibling Transplantation: Crucial Role of Timing.

[2902] Tacrolimus Concentrations in Hematopoetic Stem Cell Transplantation Patients Are Related to Cytochrome P450 3A5 Gene Polymorphisms.

[2903] Graft vs. HTLV-I Virus Effect Can Be Induced Independently of Graft vs. Leukemia Effect in Patients with Adult T-Cell Leukemia Who Received Allogeneic Hematopoietic Stem Cell Transplantation.

[2904] Allo-Reactive NK Cells after HLA-Matched Allogeneic Hematopoietic Stem Cell Transplantation.

[2905] Evaluation of Pre-Transplantation T-Cell Receptor Excision Circles (TREC) in Reduced-Intensity Stem Cell Transplantation (RIST) Recipients.

[2906] Allotype Reagents Distinguish Donor and Recipient Antibodies after Hematopoietic Transplantation.

[2907] Rituximab Infusion Two Months after Nonmyeloablative Transplantation Maintains B-Cell Disease Control with Minimal GVHD.

[2908] Oligonucleotide Microarray Analysis of Gene Expression Profiles in Chronic Graft-Versus-Host Disease (GVHD) after Allogeneic Hematopoietic Stem Cell Transplantation.

[2909] Asymmetric Reconstitution of γδ T Cell Subsets after Haemopoietic Stem Cell Transplantation.

[2910] The Effect of Donor CD4⁺CD25⁺ Regulatory T Cells on Hematopoietic and Immune Reconstitution, GVHD and Disease-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation.

[2911] Clinical Correlation of Foxp3 Regulatory Gene Expressions and NK Cells in Early Engraftment after Myeloablative Allogeneic Stem Cell Transplantation.

[2912] Two Independent Effects of Immunoglobulin-Like Receptor (KIR) Allele Matching between Siblings: Inhibitory KIR (iKIR) Mismatches Are Associated with Graft Versus Host Disease (GVHD) While Activatory KIR Matches (aKIR) and cGVHD Are Associated with Graft Versus Leukemia (GVL).

[2913] Use of Fluid-Ventilated, Gas-Permeable Scleral Lens (SL) for Management of Severe Keratoconjunctivitis Sicca Secondary to Chronic Graft-Versus-Host Disease.

[2914] Day 15 Natural Killer (NK) Cell Recovery Predicts Progression Free Survival after Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma.

[2915] Decreased Serum Levels of Surfactant Protein D (SP-D) Prior Transplant Is Associated with the Development of Bronchiolitis Obliterans (BO) and Idiopathic Pneumonia Syndrome (IPS) Following Allogeneic Hematopoietic Stem Cell Transplantation.

[2916] Differences in Immune Reconstitution and Cytokine Production in Children with Sibling Donor BMT Versus T-Cell Depleted PBSCT from Unrelated or Mismatched Family Donors.

[2917] Cyclosporin A Kinetics in Children after Stem Cell Transplantation.

[2919] Incidence and Risk Factors for Developing Limbic Encephalitis in Allogeneic Stem Cell Transplantation.

Clinical Care: Infectious Complications of Transplantation

[2920] Profound T Cell Depletion Does Not Eradicate CMV Specific CD8 T Cells Responsible for Protective Immunity to CMV after T Cell Depleted Allogeneic Stem Cell Transplantation.

[2921] HBV Reverse Seroconversion and Intervention with Vaccination after Allogeneic HSCT in Patients with Previous HBV Infection.

[2922] Pilot Trial of Rituximab for the Prevention of Epstein Barr Virus B Cell Lymphoproliferative Disorder (EBV-LPD) Following T Cell Depleted (TCD) Unrelated or HLA-Mismatched Related Hematopoietic Stem Cell Transplantation.

[2923] Double Cord Blood Transplantation for Patients with High Risk Hematological Diseases: Delayed Immune Recovery and High Incidence of Infections.